| Treatment modality/category | Specific therapies/approaches | Indications and patient selection criteria | Response rates and outcomes | Key side effects/considerations | Evidence level/source |
|---|---|---|---|---|---|
| Radiotherapy | Local radiotherapy to isolated plasmacytoma/osteosclerotic lesion(s); typically curative-intent doses **≥40 Gy** | Best for **no bone marrow involvement** and **1–3 bone lesions**; used when disease is focal rather than diffuse/systemic; imaging (especially FDG-PET/CT) helps identify active target lesions and decide focal vs systemic therapy (pqac-00000005, pqac-00000007) | Mayo cohort cited in review: **6-year PFS 62%** in **82 patients** treated with radiotherapy, with no difference between 1 vs 2 vs 3 lesions; effective but often **slow to work** (pqac-00000005) | Slower onset than systemic therapy; may be paired with dexamethasone or lenalidomide/dexamethasone while awaiting response; inappropriate for diffuse marrow/systemic disease (pqac-00000005) | Retrospective cohort and expert-review evidence; summarized as standard-of-care for focal disease in review literature (pqac-00000005, pqac-00000013) |
| Autologous stem cell transplantation (ASCT) | High-dose melphalan-conditioned ASCT (**melphalan 140 or 200**) with supportive optimization/bridging; priming with dexamethasone, thalidomide, or lenalidomide sometimes used before transplant (pqac-00000004, pqac-00000005) | **Treatment of choice** when radiotherapy is not suitable and patient performance status permits; generally for systemic disease or multifocal involvement; not ideal for frail patients, age **>70**, or major cardiopulmonary compromise without prior optimization (pqac-00000004, pqac-00000005) | Best outcomes among major modalities in review: **5-year OS 90–95%** and **5-year PFS 63–76%**; review also notes overall contemporary survival improvements in treated cohorts (pqac-00000004, pqac-00000005) | **Engraftment syndrome** 7–15 days post-transplant: fluid overload/weight gain, respiratory compromise, skin eruption, diarrhea, can be fatal; dexamethasone or lenalidomide pre-optimization may reduce risk; transplant candidacy limited by cardiopulmonary/renal disease and volume overload (pqac-00000004, pqac-00000005) | Retrospective transplant cohorts and expert reviews; strongest long-term outcome data among therapies in Keddie review (pqac-00000004, pqac-00000005, pqac-00000007) |
| Immunomodulatory drugs (IMiDs): lenalidomide | Lenalidomide plus dexamethasone; low-dose lenalidomide regimens also used; used frontline, relapsed/refractory, or as bridge to later ASCT (pqac-00000004, pqac-00000005) | Patients **unfit for immediate ASCT**, bridging therapy to improve fitness for later ASCT, relapsed disease, or systemic disease requiring non-transplant therapy (pqac-00000004) | Systematic review of **51 patients** cited in review: **≥VGPR 58%**, **PR 37%**, **VEGF reduced in all cases**, **neuropathy improved in 92%**, estimated **12-month PFS 94%**; prospective trial in **18 patients** reported clinical/neurologic improvement, **all alive** at median **39 months**, **3-year PFS 59%** (pqac-00000004) | **Prothrombotic**; caution in patients with venous/arterial thrombosis, thrombocytosis, or polycythemia; requires thrombosis-risk assessment; generally favored over thalidomide when neuropathy is prominent (pqac-00000004, pqac-00000005) | Systematic review, prospective trial, retrospective series summarized in Keddie review (pqac-00000004, pqac-00000005, pqac-00000013) |
| Immunomodulatory drugs (IMiDs): thalidomide | Thalidomide **100–300 mg/day** plus dexamethasone; also sometimes used as transplant-priming/bridging therapy (pqac-00000004) | Alternative systemic option where lenalidomide unavailable or unsuitable; has trial evidence but often limited by neurotoxicity (pqac-00000004) | J-POST trial of **25 patients**: greater **VEGF reduction** and possible **motor improvement** versus dexamethasone alone; additional support from smaller prospective studies/case series (pqac-00000004) | Major limitation is **treatment-emergent neuropathy**; cumulative dose **>50 g** can worsen neuropathy and confound neurologic recovery assessment (pqac-00000004) | Randomized placebo-controlled trial plus prospective/case-series evidence summarized in Keddie review (pqac-00000004, pqac-00000007) |
| Proteasome inhibitors | **Bortezomib**-based combinations, particularly **bortezomib + cyclophosphamide + dexamethasone**; investigational interest in **ixazomib** combinations (pqac-00000004) | Systemic disease needing plasma-cell directed therapy, especially when rapid hematologic/VEGF response desired; often considered when ASCT unsuitable or as part of induction strategies (pqac-00000004) | Review-cited study of **20 patients**: **complete hematologic response 41%**, **partial response 35%**, **VEGF response 88%**, median **ONLS improved from 5 to 3** (pqac-00000004) | **Peripheral neuropathy** can occur with bortezomib and may confound neurologic outcome assessment; newer proteasome inhibitors may be less neurotoxic but data are limited (pqac-00000004) | Small prospective/retrospective series; promising but less mature evidence base than ASCT/lenalidomide (pqac-00000004) |
| Alkylating agents: melphalan-based | **Melphalan + dexamethasone** for 12 cycles in non-transplant setting; high-dose melphalan also used as ASCT conditioning (separate ASCT row) (pqac-00000004, pqac-00000013) | Patients not proceeding directly to ASCT and needing systemic therapy; historical standard option in systemic disease (pqac-00000004) | Prospective trial cited in review: **31 patients**, **hematologic response 81%**, including **38% complete response**; **100% had VEGF reduction**; **all alive without progression** at median **21 months**; ONLS improved in all within **15 months** (pqac-00000004) | Cytotoxic/alkylator toxicity considerations; less favored than ASCT when transplant feasible; used as standard non-transplant systemic regimen in some settings (pqac-00000004) | Prospective trial summarized in review (pqac-00000004, pqac-00000013) |
| Alkylating agents: cyclophosphamide-based | Cyclophosphamide alone or in combinations; also commonly used as **mobilization/bridging** rather than definitive long-term monotherapy in some centers (pqac-00000004) | Often used for **stem cell mobilization** or as part of combination regimens; selected when ASCT planned or other chemotherapy needed (pqac-00000004) | Retrospective cohorts only; review notes alkylator-based therapy grouped with chemotherapy had **worse 10-year OS (46%)** in Mayo data, likely reflecting **selection bias/poorer baseline fitness** rather than intrinsic inferiority alone (pqac-00000004) | Less robust prospective efficacy data; outcomes may appear worse because sicker, non-transplant candidates receive it; role often supportive/bridging rather than preferred definitive therapy (pqac-00000004) | Retrospective cohort evidence, expert-practice commentary (pqac-00000004) |
| Corticosteroids | **Dexamethasone** alone or in combinations; 40 mg/day for 4 days in some schedules; used with radiotherapy, IMiDs, or as pre-ASCT optimization (pqac-00000004, pqac-00000005) | Adjunct across many settings: while awaiting radiotherapy effect, in combination systemic therapy, or to reduce fluid overload/inflammatory burden before transplant (pqac-00000005) | Usually not curative alone; comparator arm in thalidomide trial was inferior for VEGF reduction; contributes to combination responses and may reduce engraftment syndrome when used pre-ASCT (pqac-00000004) | Steroid toxicities; insufficient as sole definitive therapy for most patients; useful as rapid bridge/supportive anti-plasma-cell therapy (pqac-00000004, pqac-00000005) | Combination-therapy backbone and expert-review guidance rather than stand-alone definitive evidence (pqac-00000004, pqac-00000005) |
| Anti-VEGF strategy | **Bevacizumab** | Conceptually attractive given high VEGF, but not recommended as routine disease-directed monotherapy (pqac-00000001, pqac-00000002, pqac-00000004) | Clinical efficacy has been **ambiguous**; no evidence of reliable recovery despite VEGF suppression (pqac-00000001, pqac-00000002, pqac-00000004) | May be **harmful**; rapid VEGF drop after sustained high levels may trigger endothelial apoptosis/capillary leak; supports concept that VEGF is a **downstream mediator**, not sole initiating driver (pqac-00000001, pqac-00000004) | Case reports/series and mechanistic interpretation summarized in reviews (pqac-00000001, pqac-00000004) |
| Emerging/ongoing therapies | **Ixazomib + lenalidomide + dexamethasone** clinical investigation; newer proteasome inhibitors (e.g., carfilzomib mentioned as theoretically less neurotoxic but not studied in POEMS); recent unobtainable literature also suggests interest in daratumumab- and ixazomib-based approaches, but detailed source text was not available in context (pqac-00000004) | Relapsed/refractory disease, transplant-ineligible disease, or attempts to reduce neurotoxicity/modernize plasma-cell therapy (pqac-00000004) | Mayo Clinic trial recruitment for **ixazomib/lenalidomide/dexamethasone (NCT02921893)** was noted in review; mature outcome data not available in retrieved context (pqac-00000004) | Evidence still limited; modern myeloma-style combinations are promising but not yet standard on the basis of the retrieved full-text evidence set (pqac-00000004) | Early clinical-trial/expert-review level evidence (pqac-00000004) |
| Supportive and rehabilitative care | Neuropathic pain treatment (e.g., gabapentin, tricyclic antidepressants), structured rehabilitation, management of endocrine disease, cardiopulmonary monitoring, thrombosis-risk mitigation, transplant fitness optimization (pqac-00000012, pqac-00000005) | Indicated for essentially all patients due to chronic disability burden and multisystem involvement (pqac-00000005, pqac-00000012) | No disease-control metrics, but critical for function, mobility, quality of life, and enabling definitive therapy; early diagnosis and intervention reduce irreversible neurologic disability (pqac-00000005, pqac-00000012) | Must be individualized; neurologic disability may persist despite hematologic response; cardiopulmonary involvement affects eligibility for intensive therapy (pqac-00000005, pqac-00000012) | Expert review and clinical management literature (pqac-00000005, pqac-00000012) |


*Table: This table summarizes major treatment modalities for POEMS syndrome, including when each approach is used, reported response and survival outcomes, and key toxicities. It is especially useful for comparing focal therapy, transplant-based therapy, and modern systemic plasma-cell directed regimens.*